| abstract |
The present application provides methods for treating human subjects suffering from Rett syndrome by administration of a PKC activator, such as bryostatin 1, other bryostatins, and bryologs. The disclosure provides, according to certain embodiments, a method comprising administering a pharmaceutically effective amount of bryostatin 1 to a subject having Rett syndrome. 【Selection chart】 None |